Invesco
CNTB

Invesco’s Connect Biopharma Holdings CNTB Stock Holding History

Invesco’s Portfolio CNTB Stock Details CNTB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-60,449
Closed -$183K – 4055
2022
Q1 		$183K Buy
60,449
+34,820
+136% +$147K ﹤0.01% 3784
2021
Q4 		$132K Buy
25,629
+16,570
+183% +$184K ﹤0.01% 3862
2021
Q3 		$219K Buy
+9,059
New +$205K ﹤0.01% 3770

Other funds holding CNTB

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Invesco's CNTB Position: Q2 2022 in Review

Invesco sold out of Connect Biopharma Holdings (CNTB) in Q2 2022, closing a stake of 60,449 shares — an estimated $183K sold.

Invesco first reported a position in CNTB in Q3 2021 and held it in 3 quarters. The position peaked at $219K in Q3 2021. 29 funds tracked by Wall St. Rank hold CNTB as of Q2 2022.

  • Invesco reported no remaining Connect Biopharma Holdings position as of Q2 2022 after selling out during the quarter.
  • Invesco sold 60,449 Connect Biopharma Holdings shares in Q2 2022, an estimated $183K.
  • Invesco first reported a position in Connect Biopharma Holdings in Q3 2021 and held it in 3 quarters.
  • Invesco's Connect Biopharma Holdings position peaked at $219K in Q3 2021.
  • 29 funds tracked by Wall St. Rank held Connect Biopharma Holdings as of Q2 2022.

Based on Invesco's 13F filing for Q2 2022, filed 15 Aug 2022.